Antibody and Reagent Development Core

核心B--项目摘要/摘要 丝状病毒是NIAID A类优先病原体，可以颠覆宿主免疫系统，促进病毒 复制，导致人间病例死亡率高达90%。丝状病毒基因组编码7到9个 蛋白质。尽管基因数量很少，但关于具体机制的信息有限，通过 哪些不同的病毒-病毒和病毒-宿主相互作用有助于丝状病毒的复制和致病，阻碍 抗病毒药物或疫苗的发展。抗体和试剂开发核心(核心B)将提供 关键试剂和对整个科学任务的支持，并促进对这些 互动。具体来说，Core B将提供一套独特的标准化抗体、细胞系和小鼠 将在研究项目(RP)和PPG核心中传播的模型。正在协商中 在管理核心(核心A)和PPG领导下，核心B将对实验进行优先排序，以确保 试剂将随时提供给RPS和岩心，用于界面的使用、验证和表征 病毒蛋白和影响丝状病毒复制周期步骤的宿主因素之间的关系。核心B将开发 小鼠抗埃博拉和马尔堡病毒蛋白的单抗和合成抗体产生敲除细胞 宿主因子行，并生成由RP01识别的选定宿主因子的条件敲除小鼠模型， RP02、RP03和核心C，当这些试剂未在市场上买到时。考虑到需要统一的 试剂开发流水线，核心B的科学核心活动是合理的。

Core B - Project Summary/Abstract Filoviruses, which are NIAID category A priority pathogens, can subvert host immune systems to facilitate viral replication, resulting in human case fatality rates as high as 90%. The filoviral genome encodes for seven to nine proteins. Despite the small number of genes, limited information is available on the specific mechanisms by which different viral-viral and viral-host interactions contribute to filoviral replication and pathogenesis, hindering the development of antivirals or vaccines. The Antibody and Reagent Development Core (Core B) will provide critical reagents and support for the overall scientific mission and facilitate the characterization of these interactions. Specifically, Core B will provide a unique set of standardized antibodies, cell-lines, and mouse models that will be disseminated amongst the Research Projects (RPs) and Cores of the PPG. In consultation with the Administrative Core (Core A) and the PPG leadership, Core B will prioritize experiments to ensure that reagents will be readily available to the RPs and Cores for use, validation, and characterization of interfaces between viral proteins and host factors that impact steps in the filoviral replication cycle. Core B will develop mouse monoclonal and synthetic antibodies against Ebola and Marburg viral proteins, generate knockout cell lines of host factors, and generate conditional knockout mouse models of select host factors identified by RP01, RP02, RP03, and Core C when such reagents are not commercially available. Given the need for a unified reagent development pipeline, the scientific core activity for Core B is justified.